Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast can...
Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Chemotherapy prior to immune checkpoint blockade (ICB) treatment appears to improve ICB efficacy but resistance to ICB remains a clinical challenge and is attributed to highly plastic myeloid cells associating with the tumor immune microenvironment (TIME). Here we show by CITE-seq single-cell transcriptomic and trajectory analyses that neoadjuvant...
Alternative Titles
Full title
Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c56b41a143f64bd2b1690c2b26be55c4
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c56b41a143f64bd2b1690c2b26be55c4
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-023-37727-y
